Natera Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $53.68
- Today's High:
- $55
- Open Price:
- $54.25
- 52W Low:
- $34.002
- 52W High:
- $63
- Prev. Close:
- $54.59
- Volume:
- 580100
Company Statistics
- Market Cap.:
- $6.26 billion
- Book Value:
- 5.227
- Revenue TTM:
- $931.05 million
- Operating Margin TTM:
- -54.94%
- Gross Profit TTM:
- $363.97 million
- Profit Margin:
- -54.97%
- Return on Assets TTM:
- -27.62%
- Return on Equity TTM:
- -98.35%
Company Profile
Natera Inc had its IPO on 2015-07-02 under the ticker symbol NTRA.
The company operates in the Healthcare sector and Diagnostics & Research industry. Natera Inc has a staff strength of 2,958 employees.
Stock update
Shares of Natera Inc opened at $54.25 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $53.68 - $55, and closed at $54.57.
This is a -0.04% slip from the previous day's closing price.
A total volume of 580,100 shares were traded at the close of the day’s session.
In the last one week, shares of Natera Inc have slipped by -12.72%.
Natera Inc's Key Ratios
Natera Inc has a market cap of $6.26 billion, indicating a price to book ratio of 11.7378 and a price to sales ratio of 5.6568.
In the last 12-months Natera Inc’s revenue was $931.05 million with a gross profit of $363.97 million and an EBITDA of $-492480000. The EBITDA ratio measures Natera Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Natera Inc’s operating margin was -54.94% while its return on assets stood at -27.62% with a return of equity of -98.35%.
In Q2, Natera Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 31.9%.
Natera Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-4.73 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Natera Inc’s profitability.
Natera Inc stock is trading at a EV to sales ratio of 5.3345 and a EV to EBITDA ratio of -7.9478. Its price to sales ratio in the trailing 12-months stood at 5.6568.
Natera Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.25 billion
- Total Liabilities
- $276.86 million
- Operating Cash Flow
- $47.03 million
- Capital Expenditure
- $8.97 million
- Dividend Payout Ratio
- 0%
Natera Inc ended 2024 with $1.25 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.25 billion while shareholder equity stood at $596.15 million.
Natera Inc ended 2024 with $0 in deferred long-term liabilities, $276.86 million in other current liabilities, 11000.00 in common stock, $-2190375000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $381.11 million and cash and short-term investments were $735.94 million. The company’s total short-term debt was $80,418,000 while long-term debt stood at $282.30 million.
Natera Inc’s total current assets stands at $1.07 billion while long-term investments were $0 and short-term investments were $354.83 million. Its net receivables were $260.07 million compared to accounts payable of $21.11 million and inventory worth $42.69 million.
In 2024, Natera Inc's operating cash flow was $47.03 million while its capital expenditure stood at $8.97 million.
Comparatively, Natera Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $54.57
- 52-Week High
- $63
- 52-Week Low
- $34.002
- Analyst Target Price
- $73.87
Natera Inc stock is currently trading at $54.57 per share. It touched a 52-week high of $63 and a 52-week low of $63. Analysts tracking the stock have a 12-month average target price of $73.87.
Its 50-day moving average was $51.67 and 200-day moving average was $48.8 The short ratio stood at 5.98 indicating a short percent outstanding of 0%.
Around 375.1% of the company’s stock are held by insiders while 9609.2% are held by institutions.
Frequently Asked Questions About Natera Inc
Similar Industry Stocks (Diagnostics & Research)
Most Active
Top Gainers
Top Losers
About
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company’s products also comprise Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company’s algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.